Sign in
ARQT Stock Price, Chart, Stats & News
Arcutis Biotherapeutics, Inc.
Save
Arcutis Biotherapeutics, Inc. (ARQT) does not currently pay a dividend.
3.29B
Market cap
125.10x
Current P/E
27.78x
Forward P/E
ARQT chart
Fundamentals
Gross margin | 90.24% |
Operating margin | -3.25% |
Pretax margin | -3.98% |
Net margin | -4.29% |
Effective tax rate | -7.82% |
ROA | -3.73% |
ROE | -10.26% |
D/E | 0.03x |
Interest coverage ratio | -1.01x |
ARQT valuation
P/E | 125.10x |
P/S | 7.00x |
P/B | 14.36x |
P/CF | -483.82x |
P/FCF | -417.05x |
P/OCF | -483.82x |
PEG | -2.64x |
EV multiple | 1013.53x |
About
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds.
Similar securities
Based on sector and market capitalization
Report issue